On March 11, 2021 RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, reported that it will report its fourth quarter and full year 2020 financial results and operational highlights on Thursday, March 18, 2021 (Press release, RedHill Biopharma, MAR 11, 2021, View Source [SID1234576473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will host a conference call and webcast on Thursday, March 18, 2021, at 8:30 a.m. EDT, during which it will present key highlights for the full year of 2020, including:

Full-year 2020 financial performance;
Commercial activities;
The ongoing Phase 2/3 studies for COVID-19 with opaganib and RHB-107;
The Phase 3 study of RHB-204 as an oral first-line treatment for pulmonary nontuberculous mycobacteria (NTM) disease

The webcast and slides will be broadcast live on the Company’s website, View Source, and will be available for replay for 30 days.